<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538848</url>
  </required_header>
  <id_info>
    <org_study_id>4010.PCT001</org_study_id>
    <nct_id>NCT02538848</nct_id>
  </id_info>
  <brief_title>Study of HTD4010 in Healthy Volunteers</brief_title>
  <official_title>A First in Human, Randomized, Double-Blind Study to Assess Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Effects of HTD4010 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighTide Biopharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighTide Biopharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety and tolerability of HTD4010 after single ascending doses (SAD) in&#xD;
      healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety, tolerability and pharmacokinetics(PK) assessments are the outcome measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity and causality of adverse events</measure>
    <time_frame>One day in SAD</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>50mg in SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 50mg HTD4010 or placebo injectable in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg in SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 100mg HTD4010 or placebo injectable in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg in SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 200mg HTD4010 or placebo injectable in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300mg in SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 300mg HTD4010 or placebo injectable in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD4010</intervention_name>
    <description>injectable solution</description>
    <arm_group_label>100mg in SAD</arm_group_label>
    <arm_group_label>200mg in SAD</arm_group_label>
    <arm_group_label>300mg in SAD</arm_group_label>
    <arm_group_label>50mg in SAD</arm_group_label>
    <other_name>analog of INGAP peptide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For volunteers in SAD:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index (BMI) ≥18.0 to ≤ 30.0 kg/m2&#xD;
&#xD;
          2. Non-diabetic, fasting plasma glucose &lt; 5.6 mmol/L&#xD;
&#xD;
          3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g.,&#xD;
             tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or&#xD;
             post-menopausal for ≥12 months.&#xD;
&#xD;
             Males must be surgically sterile, abstinent or if engaged in sexual relations of&#xD;
             child-bearing potential, the participant and his partner must be using an acceptable,&#xD;
             highly effective, contraceptive method from screening and for a period of 60 days&#xD;
             after the last dose of Study Drug.&#xD;
&#xD;
          4. Ability to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systolic blood pressure &gt;160 mmHg and/or diastolic blood pressure &gt;90 mmHg at&#xD;
             screening.&#xD;
&#xD;
          2. Pregnant or lactating women&#xD;
&#xD;
          3. Participation in an investigational study within 30 days prior to dosing or 5&#xD;
             half-lives within the last dose of investigational product whichever is longer.&#xD;
&#xD;
          4. Current use of any prescription or over-the-counter (OTC) medications, including&#xD;
             herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives,&#xD;
             whichever is longer. Use of ≤2g paracetamol per day is allowed prior to and during the&#xD;
             study at Investigator discretion.&#xD;
&#xD;
          5. Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing.&#xD;
&#xD;
          6. History of any major surgery within 6 months prior to Screening&#xD;
&#xD;
          7. History of any serious adverse reaction or hypersensitivity to any of the product&#xD;
             components.&#xD;
&#xD;
          8. Use of parenterally administered proteins or antibodies within 12 weeks of screening.&#xD;
&#xD;
        etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janakan Krishnarajah, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Perth</city>
        <zip>WA6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

